<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00070278</url>
  </required_header>
  <id_info>
    <org_study_id>CRUK-neo-tAnGo</org_study_id>
    <secondary_id>CDR0000331863</secondary_id>
    <secondary_id>EU-20316</secondary_id>
    <nct_id>NCT00070278</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Epirubicin, Cyclophosphamide, and Paclitaxel With or Without Gemcitabine in Treating Women Who Are Undergoing Surgery for Early Breast Cancer</brief_title>
  <official_title>A Phase III Randomized Neoadjuvant Study of Sequential Epirubicin/Cyclophosphamide and Paclitaxel + - Gemcitabine in Poor Risk Early Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cambridge University Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as epirubicin, cyclophosphamide, paclitaxel, and&#xD;
      gemcitabine use different ways to stop tumor cells from dividing so they stop growing or die.&#xD;
      Giving combination chemotherapy before surgery may shrink the tumor so that it can be removed&#xD;
      during surgery. It is not yet known which combination chemotherapy regimen is more effective&#xD;
      in treating early breast cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying different regimens of combination&#xD;
      chemotherapy to compare how well they work in treating women who are undergoing surgery for&#xD;
      early invasive breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare the complete pathological response rate in women with poor-risk early breast&#xD;
           cancer treated with neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel&#xD;
           with vs without gemcitabine.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare the disease-free and overall survival of patients treated with these regimens.&#xD;
&#xD;
        -  Compare the toxicity of these regimens in these patients.&#xD;
&#xD;
        -  Compare the effect of these regimens on prognostic factors in these patients.&#xD;
&#xD;
        -  Correlate molecular profiles, specific gene mutations, and genomic and gene expression&#xD;
           changes with clinical outcome in these patients.&#xD;
&#xD;
        -  Compare the quality of life of patients treated with these regimens.&#xD;
&#xD;
        -  Determine the health economics associated with this study.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to&#xD;
      estrogen-receptor status (negative vs greater than 10% positive cells), HER-2 status&#xD;
      (positive vs negative), tumor size (30-50 mm vs greater than 50 mm), and clinical involvement&#xD;
      of axillary nodes (yes vs no). Patients are randomized to 1 of 4 treatment arms.&#xD;
&#xD;
        -  Neoadjuvant sequential chemotherapy:&#xD;
&#xD;
             -  Arm I: Patients receive epirubicin IV and cyclophosphamide IV on day 1. Treatment&#xD;
                repeats every 21 days for 4 courses. Patients then receive paclitaxel IV over 3&#xD;
                hours on day 1. Treatment repeats every 21 days for 4 courses.&#xD;
&#xD;
             -  Arm II: Patients receive paclitaxel as in arm I followed by epirubicin and&#xD;
                cyclophosphamide as in arm I.&#xD;
&#xD;
             -  Arm III: Patients receive epirubicin and cyclophosphamide as in arm I followed by&#xD;
                paclitaxel as in arm I and gemcitabine IV over 30 minutes on days 1 and 8.&#xD;
                Treatment repeats every 21 days for 4 courses.&#xD;
&#xD;
             -  Arm IV: Patients receive paclitaxel as in arm I and gemcitabine as in arm III&#xD;
                followed by epirubicin and cyclophosphamide as in arm I.&#xD;
&#xD;
        -  Surgery: After completion of neoadjuvant chemotherapy, patients in all arms undergo&#xD;
           definitive surgery.&#xD;
&#xD;
      Tumor tissue is removed from a subset of patients during serial biopsies. Molecular and&#xD;
      genetic profiling, mutation analysis, and comparative genomic analysis is performed on the&#xD;
      tissue samples.&#xD;
&#xD;
      Quality of life is assessed at baseline, after 4 courses of chemotherapy, after the&#xD;
      completion of chemotherapy, after surgery, and then every 6 months for 2 years.&#xD;
&#xD;
      Patients are followed every 2 months for 2 years and then every 3 months for 3 years.&#xD;
&#xD;
      Peer Reviewed and Funded or Endorsed by Cancer Research UK&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 800 patients (200 per treatment arm) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2005</start_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Complete pathological response after 4 courses</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of prognostic factors</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epirubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>comparative genomic hybridization</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>microarray analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>mutation analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed invasive breast cancer&#xD;
&#xD;
               -  Grade 2 or 3&#xD;
&#xD;
          -  Tumor size at least 3 cm by ultrasound&#xD;
&#xD;
          -  No evidence of metastatic disease&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Fit to receive study chemotherapy&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helena Earl, MBBS, PhD, FRCP</last_name>
    <affiliation>Cambridge University Hospitals NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Addenbrooke's Hospital at Cambridge University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Cambridge</city>
        <state>England</state>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <study_first_submitted>October 3, 2003</study_first_submitted>
  <study_first_submitted_qc>October 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2003</study_first_posted>
  <last_update_submitted>August 6, 2013</last_update_submitted>
  <last_update_submitted_qc>August 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2013</last_update_posted>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

